Trial of Mesna to Prevent Doxorubicin-induced Plasma Protein Oxidation and Tumor Necrosis Factor Alpha (TNF-α) Release
Status:
Completed
Trial end date:
2015-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether the drug mesna is able to block a series of
chemical changes that occur in the blood of patients who receive the chemotherapy medicine
doxorubicin. The researchers believe these blood chemical changes may the cause of "cloudy
thinking" or "chemobrain" that are reported by some patients receiving chemotherapy.